Defcort 24 mg (Deflazacort)

Product Overview

n

Defcort 24 mg is a pharmaceutical preparation that contains the corticosteroid deflazacort as its active ingredient. It is manufactured by Macleods Pharmaceuticals Pvt Ltd, a company with a reputation for producing high‑quality generic medicines in India. The product is presented in a strip that holds ten tablets, each tablet delivering a strength of 24 mg of deflazacort. Pack size options include 30, 60, and 90 tablets, allowing patients and caregivers to select the quantity that best matches their treatment plan. The medication is classified under the allergy therapeutic category and is specifically indicated for the management of severe allergic reactions, such as those that may occur in asthma exacerbations, angio‑edema, or chronic urticaria. Shipping typically takes between six and fifteen days, depending on the destination and the logistics provider.

nn

What is Defcort 24 mg

n

Deflazacort belongs to the class of glucocorticoids, which are synthetic analogues of naturally occurring hormones produced by the adrenal cortex. The molecule works by modulating the body’s immune response, reducing inflammation, and stabilizing cell membranes that are involved in the release of inflammatory mediators. In the context of severe allergic reactions, deflazacort helps to dampen the overactive immune activity that leads to swelling, itching, and airway constriction. Although the exact chemical structure of deflazacort differs slightly from other corticosteroids such as prednisone or dexamethasone, its pharmacological profile is similar: it binds to the glucocorticoid receptor inside target cells and alters gene transcription pathways that control inflammation and immune cell trafficking. The 24 mg tablet strength is designed to provide a dose that is potent enough for acute symptom control while minimizing the risk of excessive systemic exposure when used as directed.

nn

Uses and Benefits

n

The primary therapeutic use of Defcort 24 mg is the treatment of severe allergic reactions that do not respond adequately to antihistamines or topical agents. Clinicians may prescribe it for conditions such as acute exacerbations of asthma, severe allergic rhinitis, atopic dermatitis, and certain autoimmune skin disorders that manifest with intense itching and rash. Because deflazacort has a relatively long half‑life compared with some other corticosteroids, it can provide sustained symptom relief with a dosing schedule that is often once daily. Patients who take Defcort often report a reduction in redness, swelling, and itching within a few hours of the first dose, and many experience improved breathing comfort when the medication is used for respiratory allergies. In addition, the oral tablet formulation is convenient for home use, eliminating the need for injections or hospital visits in many cases.

nn

How It Works

n

Deflazacort exerts its anti‑allergic effect through multiple intracellular pathways. Upon absorption into the bloodstream, the drug penetrates target cells such as lymphocytes, macrophages, and eosinophils. Inside these cells, deflazacort binds to the intracellular glucocorticoid receptor, forming a complex that translocates into the nucleus. Once in the nucleus, the complex influences the expression of genes that regulate cytokine production, adhesion molecule activity, and inflammatory enzyme synthesis. By decreasing the transcription of pro‑inflammatory cytokines such as interleukin‑1, interleukin‑6, and tumor necrosis factor‑alpha, Defcort reduces the cascade of events that lead to vasodilation, increased vascular permeability, and bronchoconstriction. Moreover, the medication stabilizes mast cells and prevents the release of histamine and other mediators that amplify allergic symptoms. This multifactorial mechanism makes Defcort an effective option for controlling severe, systemic allergic responses. The drug’s effect is well documented by the NIH (NIH).

nn

Dosage Guidelines

n

Dosage of Defcort 24 mg should always be individualized by a qualified healthcare professional based on the severity of the allergic condition, the patient’s age, weight, renal and hepatic function, and any concomitant medications. In adult patients, a typical initial dose for a severe allergic episode may range from 24 mg to 48 mg administered once daily for a short period, followed by a tapering schedule to prevent adrenal suppression. Pediatric dosing is calculated per kilogram of body weight and must be adjusted according to clinical response. Patients are advised to take the tablet with food or milk to reduce gastrointestinal irritation, and they should not crush or split the tablet unless a healthcare provider specifically instructs otherwise. It is essential to adhere to the prescribed duration of therapy; abrupt discontinuation can lead to a rebound of symptoms or adrenal insufficiency. If a dose is missed, the patient should not double the next dose but should resume the regular schedule as soon as possible.

nn

Side Effects

n

Like all corticosteroids, Defcort 24 mg can produce side effects, although many individuals tolerate the medication well when used at the lowest effective dose and for the shortest necessary duration. Common adverse reactions include increased appetite, mild weight gain, trouble sleeping, and mood changes such as irritability or anxiety. Gastrointestinal discomfort, including heartburn or indigestion, may also occur. More serious, though less frequent, side effects can involve elevated blood pressure, high blood glucose levels, and electrolyte imbalances, which may be particularly relevant for patients with diabetes or hypertension. Long‑term use of oral corticosteroids can lead to bone density loss, cataracts, and ocular hypertension, so regular monitoring by a physician is recommended for patients on extended therapy. If any signs of severe allergic reaction to the medication itself — such as rash, swelling, or difficulty breathing — appear, the drug should be discontinued and emergency medical care sought immediately.

nn

Warnings and Precautions

n

Before initiating treatment with Defcort, clinicians should assess the patient’s medical history for conditions that may be exacerbated by corticosteroid therapy, including uncontrolled infections, peptic ulcer disease, severe psychiatric disorders, and certain cardiovascular diseases. Pregnant or breastfeeding women should only use Defcort if the potential benefit outweighs the possible risk to the fetus or infant, and they must do so under the guidance of a physician. Patients scheduled for surgery should inform their surgeon of all medications, including Defcort, because the drug can affect stress response and wound healing. It is also important to avoid concurrent use of live vaccines while on high‑dose corticosteroid therapy, as this can impair vaccine efficacy and increase infection risk. Drug interactions may occur with immunosuppressants, anticoagulants, and certain antihypertensive agents, so a complete medication list should be reviewed before prescribing. The FDA provides additional guidance on corticosteroid safety (FDA). Finally, abrupt discontinuation after prolonged therapy can precipitate adrenal insufficiency; therefore, any dose reduction should be performed gradually under medical supervision.

nn

Frequently Asked Questions

n

n